JP2022516557A5 - - Google Patents
Info
- Publication number
- JP2022516557A5 JP2022516557A5 JP2021538982A JP2021538982A JP2022516557A5 JP 2022516557 A5 JP2022516557 A5 JP 2022516557A5 JP 2021538982 A JP2021538982 A JP 2021538982A JP 2021538982 A JP2021538982 A JP 2021538982A JP 2022516557 A5 JP2022516557 A5 JP 2022516557A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding domain
- domain binds
- cancer
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024185692A JP2025013911A (ja) | 2019-01-07 | 2024-10-22 | 修飾il-2ポリペプチドを含むポリペプチド及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789075P | 2019-01-07 | 2019-01-07 | |
| US62/789,075 | 2019-01-07 | ||
| PCT/US2020/012296 WO2020146221A1 (en) | 2019-01-07 | 2020-01-06 | Polypeptides comprising modified il-2 polypeptides and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024185692A Division JP2025013911A (ja) | 2019-01-07 | 2024-10-22 | 修飾il-2ポリペプチドを含むポリペプチド及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022516557A JP2022516557A (ja) | 2022-02-28 |
| JP2022516557A5 true JP2022516557A5 (cg-RX-API-DMAC7.html) | 2023-01-19 |
| JP7594161B2 JP7594161B2 (ja) | 2024-12-04 |
Family
ID=69374426
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021538982A Active JP7594161B2 (ja) | 2019-01-07 | 2020-01-06 | 修飾il-2ポリペプチドを含むポリペプチド及びその使用 |
| JP2024185692A Pending JP2025013911A (ja) | 2019-01-07 | 2024-10-22 | 修飾il-2ポリペプチドを含むポリペプチド及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024185692A Pending JP2025013911A (ja) | 2019-01-07 | 2024-10-22 | 修飾il-2ポリペプチドを含むポリペプチド及びその使用 |
Country Status (15)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101520534B1 (ko) | 2012-05-07 | 2015-05-21 | 고려대학교 산학협력단 | 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법 |
| IL321812A (en) | 2017-08-03 | 2025-08-01 | Synthorx Inc | Cytokine complexes for the treatment of autoimmune diseases |
| CN115710576A (zh) | 2018-02-01 | 2023-02-24 | Nkmax有限公司 | 产生天然杀伤细胞的方法和用于治疗癌症的组合物 |
| TW202031284A (zh) | 2018-11-08 | 2020-09-01 | 美商新索思股份有限公司 | 介白素10結合物及其用途 |
| MA54952A (fr) | 2019-02-06 | 2022-05-11 | Synthorx Inc | Conjugués d'il-2 et méthodes d'utilisation de ceux-ci |
| CA3148135A1 (en) | 2019-08-23 | 2021-03-04 | Carolina E. CAFFARO | Il-15 conjugates and uses thereof |
| WO2021050554A1 (en) | 2019-09-10 | 2021-03-18 | Synthorx, Inc. | Il-2 conjugates and methods of use to treat autoimmune diseases |
| CN115916831A (zh) * | 2020-06-30 | 2023-04-04 | Gi 医诺微新 | 包含抗lag-3抗体和il-2的融合蛋白及其用途 |
| EP4175979A2 (en) * | 2020-07-02 | 2023-05-10 | Inhibrx, Inc. | Polypeptides comprising modified il-2 polypeptides and uses thereof |
| KR20230112632A (ko) | 2020-10-23 | 2023-07-27 | 애셔 바이오테라퓨틱스, 인크. | 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합 |
| WO2022099090A1 (en) * | 2020-11-06 | 2022-05-12 | Xencor, Inc. | Heterodimeric antibodies that bind tgfbrii |
| EP4251187A4 (en) | 2020-11-25 | 2025-09-10 | Xilio Dev Inc | TUMOR-SPECIFIC CLASSIBLE LINKERS |
| JP2023553216A (ja) * | 2020-12-09 | 2023-12-20 | アシャ バイオセラピューティクス,インク. | 遺伝子操作細胞療法のための標的化サイトカイン構築物 |
| CN112979782B (zh) * | 2021-03-08 | 2023-07-18 | 深圳市乐土生物医药有限公司 | 一种多肽及其用途 |
| CA3213751A1 (en) * | 2021-03-31 | 2022-10-06 | Ziyang Zhong | Fusion proteins, pharmaceutical compositions, and therapeutic applications |
| TW202321283A (zh) * | 2021-07-20 | 2023-06-01 | 美商英伊布里克斯公司 | Cd8結合多肽及其用途 |
| TW202309102A (zh) * | 2021-07-20 | 2023-03-01 | 美商英伊布里克斯公司 | 靶向cd8之經修飾il-2多肽及其用途 |
| TW202319397A (zh) * | 2021-08-30 | 2023-05-16 | 美商英伊布里克斯公司 | NKp46結合多肽及其用途 |
| TW202328171A (zh) * | 2021-08-30 | 2023-07-16 | 美商英伊布里克斯公司 | 靶向NKp46之經修飾之IL-2多肽及其用途 |
| JP2024536840A (ja) * | 2021-09-26 | 2024-10-08 | ウーシー バイオロジクス アイルランド リミテッド | Il-2バリアント及びその融合タンパク質 |
| TW202334193A (zh) * | 2022-01-05 | 2023-09-01 | 美商英伊布里克斯公司 | 靶向γδ T細胞之經修飾IL-2多肽及其用途 |
| WO2024026449A2 (en) * | 2022-07-28 | 2024-02-01 | Proviva Therapeutics (Hong Kong) Limited | Il-2 procytokine antibody fusion proteins |
| WO2025151752A1 (en) | 2024-01-10 | 2025-07-17 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| EP1454138B1 (en) * | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| DK1678314T3 (da) | 2003-10-22 | 2012-12-03 | Keck Graduate Inst | Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi |
| CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| KR20070003934A (ko) * | 2004-03-05 | 2007-01-05 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템 |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| CN102101885B (zh) | 2010-09-01 | 2013-06-05 | 南京发士达生物科技有限公司 | 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途 |
| CN105440123B (zh) * | 2011-02-10 | 2020-10-09 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
| WO2013180200A1 (ja) * | 2012-05-30 | 2013-12-05 | 中外製薬株式会社 | 標的組織特異的抗原結合分子 |
| PT3102595T (pt) * | 2014-02-06 | 2019-01-11 | Hoffmann La Roche | Proteínas de fusão de interleucina-2 e suas utilizações |
| IL304950A (en) | 2015-04-10 | 2023-10-01 | Amgen Inc | Interleukin for the expansion of myotonic control T-2 cells |
| EP3402818A1 (en) * | 2016-01-11 | 2018-11-21 | Universität Zürich | Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent |
| KR20240115933A (ko) * | 2016-05-04 | 2024-07-26 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
| KR20240005989A (ko) * | 2017-03-15 | 2024-01-12 | 큐 바이오파마, 인크. | 면역 반응을 조절하는 방법 |
| JP7148539B2 (ja) * | 2017-04-03 | 2022-10-05 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 免疫抱合体 |
| CA3052532A1 (en) * | 2017-04-05 | 2018-10-11 | F. Hoffmann-La Roche Ag | Bispecific antibodies specifically binding to pd1 and lag3 |
| AU2018273914A1 (en) * | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| AU2018287317B2 (en) * | 2017-06-19 | 2024-06-20 | Medicenna Therapeutics Inc. | Uses and methods for IL-2 superagonists, agonists, and fusions thereof |
-
2020
- 2020-01-06 CN CN202080018011.6A patent/CN113924311A/zh active Pending
- 2020-01-06 JP JP2021538982A patent/JP7594161B2/ja active Active
- 2020-01-06 EP EP20702547.9A patent/EP3908596A1/en active Pending
- 2020-01-06 TW TW109100336A patent/TWI874345B/zh active
- 2020-01-06 US US17/418,458 patent/US20220089667A1/en active Pending
- 2020-01-06 CA CA3125529A patent/CA3125529A1/en active Pending
- 2020-01-06 MX MX2021008147A patent/MX428580B/es unknown
- 2020-01-06 AR ARP200100028A patent/AR117770A1/es unknown
- 2020-01-06 AU AU2020206672A patent/AU2020206672B2/en active Active
- 2020-01-06 KR KR1020217024431A patent/KR20210113265A/ko active Pending
- 2020-01-06 SG SG11202106700WA patent/SG11202106700WA/en unknown
- 2020-01-06 BR BR112021012294-0A patent/BR112021012294A2/pt unknown
- 2020-01-06 WO PCT/US2020/012296 patent/WO2020146221A1/en not_active Ceased
-
2021
- 2021-07-05 IL IL284633A patent/IL284633A/en unknown
- 2021-07-05 CL CL2021001779A patent/CL2021001779A1/es unknown
-
2024
- 2024-10-22 JP JP2024185692A patent/JP2025013911A/ja active Pending
-
2025
- 2025-12-19 AU AU2025283608A patent/AU2025283608A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023532904A5 (cg-RX-API-DMAC7.html) | ||
| Chen et al. | Bispecific antibodies in cancer immunotherapy | |
| JP5851419B2 (ja) | ヘテロダイマー結合タンパク質およびその使用 | |
| Weidle et al. | Tumor-antigen–binding bispecific antibodies for cancer treatment | |
| US11952421B2 (en) | Bispecific antibodies against CD3EPSILON and ROR1 | |
| JP6702893B2 (ja) | 多重特異的抗原結合タンパク質 | |
| Godar et al. | Therapeutic bispecific antibody formats: a patent applications review (1994-2017) | |
| FI3749346T3 (fi) | Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät | |
| US20220089722A1 (en) | Heterodimeric fusion protein | |
| CN115066274A (zh) | 三价结合分子 | |
| JP2024534468A5 (cg-RX-API-DMAC7.html) | ||
| WO2023051727A1 (zh) | 结合cd3的抗体及其用途 | |
| CA3125120A1 (en) | Antibody fusion protein, preparation method therefor and application thereof | |
| CN115836084A (zh) | 多特异性免疫调节剂 | |
| JP2024521701A (ja) | 抗cd137抗体及びその使用方法 | |
| JP2025504795A5 (cg-RX-API-DMAC7.html) | ||
| Brinkmann et al. | The making of multispecific immunoglobulins–a clinical perspective | |
| RU2021123226A (ru) | Полипептиды, содержащие модифицированный полипептид il-2, и их применения | |
| US20250376524A1 (en) | Tetravalent multispecific binding molecules and methods of use thereof | |
| WO2025201240A1 (en) | Antibodies targeting cd3, cd28, and pd-l1 and uses thereof | |
| WO2023199927A1 (ja) | がん治療におけるpd-1シグナル阻害剤との組み合わせによる抗tspan8-抗cd3二重特異性抗体の使用 | |
| WO2025167357A1 (zh) | Cd80/taa融合蛋白相关的肿瘤靶向、t细胞激活分子形式及其应用 | |
| WO2023219121A1 (ja) | 抗taa-抗cd3多重特異性抗体 | |
| TW202434635A (zh) | 多特異性抗體及其醫藥用途 | |
| KR20260062933A (ko) | 항-γδ TCR 항체 및 이의 용도 |